MedTrace Logo

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

NCT02703779 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2021-06-18

Study results available
· View outcomes & findings →

Summary

Explore stem cell collection with or without bortezomib with in-vivo purging in multiple myeloma.

Conditions

Interventions

DRUG

Bortezomib

Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.

DRUG

Granulocyte colony-stimulating factor (G-CSF)

Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.

DRUG

Mozobil

Mozobil will be given to all participants by injection under the skin only if needed per Investigator.

Sponsors & Collaborators

  • Siddhartha Ganguly

    lead OTHER

Principal Investigators

  • Siddhartha Ganguly, MD · The University of Kansas - Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-10-04
Completion
2020-04-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02703779 on ClinicalTrials.gov